

Fabien Guidez

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7841579/publications.pdf>

Version: 2024-02-01

29
papers

2,131
citations

516710

16
h-index

552781

26
g-index

30
all docs

30
docs citations

30
times ranked

2680
citing authors

#	ARTICLE	IF	CITATIONS
1	Distinct interactions of PML-RAR $\hat{\pm}$ and PLZF-RAR $\hat{\pm}$ with co-repressors determine differential responses to RA in APL. <i>Nature Genetics</i> , 1998, 18, 126-135.	21.4	566
2	Reduced Retinoic Acid-Sensitivities of Nuclear Receptor Corepressor Binding to PML- and PLZF-RAR $\hat{\pm}$ Underlie Molecular Pathogenesis and Treatment of Acute Promyelocytic Leukemia. <i>Blood</i> , 1998, 91, 2634-2642.	1.4	291
3	Translocations of the RAR $\hat{\pm}$ gene in acute promyelocytic leukemia. <i>Oncogene</i> , 2001, 20, 7186-7203.	5.9	206
4	Juvenile myelomonocytic leukemia displays mutations in components of the RAS pathway and the PRC2 network. <i>Nature Genetics</i> , 2015, 47, 1334-1340.	21.4	152
5	The Histone Deacetylase 9 Gene Encodes Multiple Protein Isoforms. <i>Journal of Biological Chemistry</i> , 2003, 278, 16059-16072.	3.4	128
6	Retinoid-Triggered Differentiation and Tumor-Selective Apoptosis of Acute Myeloid Leukemia by Protein Kinase A-Mediated Desubordination of Retinoid X Receptor. <i>Cancer Research</i> , 2005, 65, 8754-8765.	0.9	111
7	Histone Acetyltransferase Activity of p300 Is Required for Transcriptional Repression by the Promyelocytic Leukemia Zinc Finger Protein. <i>Molecular and Cellular Biology</i> , 2005, 25, 5552-5566.	2.3	99
8	HDAC4 as a potential therapeutic target in neurodegenerative diseases: a summary of recent achievements. <i>Frontiers in Cellular Neuroscience</i> , 2015, 9, 42.	3.7	90
9	Colocalization and heteromerization between the two human oncogene POZ/zinc finger proteins, LAZ3 (BCL6) and PLZF. <i>Oncogene</i> , 2000, 19, 6240-6250.	5.9	66
10	Synthesis and Evaluation of a Potent and Selective Cell-Permeable p300 Histone Acetyltransferase Inhibitor. <i>Journal of the American Chemical Society</i> , 2005, 127, 17182-17183.	13.7	63
11	RAR $\hat{\pm}$ -PLZF overcomes PLZF-mediated repression of CRABPI, contributing to retinoid resistance in t(11;17) acute promyelocytic leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 18694-18699.	7.1	62
12	Acute Promyelocytic Leukemia: A Paradigm for Differentiation Therapy. <i>Cancer Treatment and Research</i> , 2009, 145, 219-235.	0.5	61
13	The epigenetic regulator PLZF represses L1 retrotransposition in germ and progenitor cells. <i>EMBO Journal</i> , 2013, 32, 1941-1952.	7.8	41
14	Regulation of Hoxb2 by APL-associated PLZF protein. <i>Oncogene</i> , 2003, 22, 3685-3697.	5.9	39
15	1 $\hat{\pm}$,25-Dihydroxyvitamin D3 Transrepresses Retinoic Acid Transcriptional Activity via Vitamin D Receptor in Myeloid Cells. <i>Molecular Endocrinology</i> , 2004, 18, 2685-2699.	3.7	37
16	Differential Utilization of Ras Signaling Pathways by Macrophage Colony-Stimulating Factor (CSF) and Granulocyte-Macrophage CSF Receptors during Macrophage Differentiation. <i>Molecular and Cellular Biology</i> , 1998, 18, 3851-3861.	2.3	31
17	An acetyltransferase assay for CREB-binding protein based on reverse phase-ultra-fast liquid chromatography of fluorescent histone H3 peptides. <i>Analytical Biochemistry</i> , 2015, 486, 35-37.	2.4	17
18	Benzodithiophenes Potentiate Differentiation of Acute Promyelocytic Leukemia Cells by Lowering the Threshold for Ligand-Mediated Corepressor/Coactivator Exchange with Retinoic Acid Receptor $\hat{\pm}$ and Enhancing Changes in all-trans-Retinoic Acid-Regulated Gene Expression. <i>Cancer Research</i> , 2005, 65, 7856-7865.	0.9	11

#	ARTICLE	IF	CITATIONS
19	Post transcriptional control of the epigenetic stem cell regulator PLZF by sirtuin and HDAC deacetylases. <i>Epigenetics and Chromatin</i> , 2015, 8, 38.	3.9	11
20	GEP analysis validates high risk MDS and acute myeloid leukemia post MDS mice models and highlights novel dysregulated pathways. <i>Journal of Hematology and Oncology</i> , 2016, 9, 5.	17.0	10
21	T-Cell Protein Tyrosine Phosphatase Is Irreversibly Inhibited by Etoposide-Quinone, a Reactive Metabolite of the Chemotherapy Drug Etoposide. <i>Molecular Pharmacology</i> , 2019, 96, 297-306.	2.3	9
22	Human CREBBP acetyltransferase is impaired by etoposide quinone, an oxidative and leukemogenic metabolite of the anticancer drug etoposide through modification of redox-sensitive zinc-finger cysteine residues. <i>Free Radical Biology and Medicine</i> , 2021, 162, 27-37.	2.9	9
23	A RP-UFLC Assay for Protein Tyrosine Phosphatases: Focus on Protein Tyrosine Phosphatase Non-Receptor Type 2 (PTPN2). <i>Scientific Reports</i> , 2015, 5, 10750.	3.3	7
24	PLZF Acetylation Levels Regulate NKT Cell Differentiation. <i>Journal of Immunology</i> , 2021, 207, 809-823.	0.8	5
25	The Benzene Hematotoxic and Reactive Metabolite 1,4-Benzoquinone Impairs the Activity of the Histone Methyltransferase SET Domain Containing 2 (SETD2) and Causes Aberrant Histone H3 Lysine 36 Trimethylation (H3K36me3). <i>Molecular Pharmacology</i> , 2021, 100, 283-294.	2.3	5
26	BCL-2 Inhibitor ABT-737 Effectively Targets Leukemia-Initiating Cells with Differential Regulation of Relevant Genes Leading to Extended Survival in a NRAS/BCL-2 Mouse Model of High Risk-Myelodysplastic Syndrome. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10658.	4.1	4
27	Retinoic Acid Receptors. , 2010, , 237-258.		0
28	Histone Acetyltransferase Activity of p300 Is Required for Transcriptional Repression by the Promyelocytic Leukemia Zinc Finger Protein.. <i>Blood</i> , 2004, 104, 359-359.	1.4	0
29	Defining the Landscape of Resistance Mutations in the Context of Modern Treatment Protocols for Acute Promyelocytic Leukemia (APL).. <i>Blood</i> , 2008, 112, 1492-1492.	1.4	0